Carbon Monoxide

Carbon Monoxide

SCHEMBL5657042

Cc1ccccc1F.[C]=O.[C]=O.[C]=O.[Cr]

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.79
TSHR P16473 3/20 0.45
CYP1A2 P05177 1/20 0.39
ALDH1A1 P00352 3/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
GAA P10253 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
KAT6A Q92794 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29488781 0.89
SCHEMBL11837 0.89
Formaldehyde SCHEMBL27341516 0.86 ACHE (0.83) ACHETSHRALDH1A1CES2CES1
SCHEMBL28557764 0.86 ACHE (0.83) ACHETSHRALDH1A1CES2CES1
Hydrochloric Acid SCHEMBL28105763 0.86 ACHE (0.94) ACHETSHRCYP1A2ALDH1A1GAA
SCHEMBL29176814 0.86
Fluoride SCHEMBL28142665 0.86
Hydrochloric Acid SCHEMBL29088489 0.86 ACHE (0.94) ACHETSHRCYP1A2ALDH1A1GAA
Fluoride SCHEMBL21816907 0.86 ACHE (0.94) ACHETSHRCYP1A2ALDH1A1GAA
Iodide SCHEMBL27592623 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226950-B2 Sodium channel modulators THERAVANCE, INC. (US) 2007-06-05 US disclosed
US-20060276467-A1 An aromatic-oxy-alkyleneamine derivative, useful for treating neuropathic pain THERAVANCE BIOPHARMA R&D IP, LLC 2006-12-07 US disclosed
US-7132422-B2 Sodium channel modulators THERAVANCE, INC. (US) 2006-11-07 US disclosed
US-20050130966-A1 Sodium channel modulators THERAVANCE BIOPHARMA R&D IP, LLC 2005-06-16 US disclosed
US-6872741-B2 Sodium channel modulators THERAVANCE, INC. (US) 2005-03-29 US disclosed
US-20040063760-A1 Sodium channel modulatiors THERAVANCE BIOPHARMA R&D IP, LLC 2004-04-01 US disclosed
US-6646012-B2 Central nervous system analgesic; hypotensive agents; antiarrhythmia agents; antidiabetic agents THERAVANCE, INC. 2003-11-11 US disclosed
US-20030065013-A1 Sodium channel modulators THERAVANCE BIOPHARMA R&D IP, LLC 2003-04-03 US disclosed
WO-2002057215-A2 SODIUM CHANNEL MODULATORS THERAVANCE, INC. (US) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130966-A1 Sodium channel modulators SCN10A, SCN5A, SCN1A ACHE 491/4885TSHR 4227/4885CYP1A2 4517/4885
US-20060276467-A1 An aromatic-oxy-alkyleneamine derivative, useful for treating neuropathic pain TRPV1, TRPA1, OPRL1 ACHE 367/4885TSHR 4384/4885CYP1A2 3434/4885
US-20040063760-A1 Sodium channel modulatiors SCN1A, SCN2A, SCN1B ACHE 420/4885TSHR 4757/4885CYP1A2 4724/4885
US-20030065013-A1 Sodium channel modulators SCN10A, SCN5A, SCN1A ACHE 491/4885TSHR 4227/4885CYP1A2 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.